



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology  
**Manuscript NO:** 38197  
**Title:** Targeted Therapy or Immunotherapy? Optimal Treatment in HCC  
**Reviewer’s code:** 03003338  
**Reviewer’s country:** China  
**Science editor:** Li-Jun Cui  
**Date sent for review:** 2018-02-07  
**Date reviewed:** 2018-02-18  
**Review time:** 11 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

1. The authors should modify the outline and the structure to make the content to corresponding to the title. 2. The authors should check the manuscript carefully to avoid repeated appearance of same data in different parts in the text. For example, the second paragraph on page 4 was seemed to be copied to be the second paragraph on page 8. 3. The numbers from the same reference differed in different parts of the text by mistake? For example, the numbers in the last paragraph on page 6 were completely different with those in the second paragraph on page 10. However, both of them refer to Ref12. 4. The Conclusion part. The authors should rewrite the session and be careful with grammatic problems. 5. The whole article should be typed carefully to leave space between words.



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 38197

**Title:** Targeted Therapy or Immunotherapy? Optimal Treatment in HCC

**Reviewer's code:** 01851506

**Reviewer's country:** Japan

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-02-13

**Date reviewed:** 2018-02-22

**Review time:** 8 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

**COMMENTS TO AUTHORS**

In this review Contratto and Wu reviewed the optimal treatment in hepatocellular carcinoma (HCC) with the tyrosine kinase inhibitors or monoclonal antibodies against the immune checkpoint inhibitors such as Programmed Death (PD)-1/PD-ligand(L)1. Furthermore, they discussed the biomarkers relevant to maximize the response of HCC treatment such as alpha-feto protein (AFP) and PD-L1, with ramucirumab (anti-VEGFR2 monoclonal antibody) and with anti-PD-L1 monoclonal antibody, respectively. Also they discussed the future direction biomarkers such as neoantigen, tumor mutational burden, and interferon gamma for HCC treatment. The review is concise but comprehensive, and easy to follow. However, there are some concerns about the accuracy of the description. (1) In page 7, Pembrolizumab is an immunotherapy that inhibits PD-1. Given Pembrolizumab is anti-PD-L1 monoclonal antibody that inhibits PD-1 - PD-L1 interaction, the above description is not accurate. (2) In page 9, In a phase II dose



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

expansion cohort study of nivolumab in HCC patients either progressed or intolerant of sorafenib, RR was 32% versus 17.2% in patients with PD  $\geq$  1% and PD-L1 < 1%, respectively[12]. The reviewer wonders which the authors discuss here, PD-1 or PD-L1? The reviewer guesses that the authors want to compare the percentage of PD-L1 between progressed HCC patients and those intolerant of sorafenib. Should comparison between "PD  $\geq$  1% and PD-L1 < 1%" be correct, the authors need to explain more.



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 38197

**Title:** Targeted Therapy or Immunotherapy? Optimal Treatment in HCC

**Reviewer's code:** 02445408

**Reviewer's country:** Cuba

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-02-13

**Date reviewed:** 2018-02-24

**Review time:** 11 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

It is a good work Need only a minor revision



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 38197

**Title:** Targeted Therapy or Immunotherapy? Optimal Treatment in HCC

**Reviewer's code:** 02994003

**Reviewer's country:** Egypt

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-02-13

**Date reviewed:** 2018-02-26

**Review time:** 12 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

The manuscript is well written. It was better if authors added more one diagrammatic figure and one or more table



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Gastrointestinal Oncology  
**Manuscript NO:** 38197  
**Title:** Targeted Therapy or Immunotherapy? Optimal Treatment in HCC  
**Reviewer’s code:** 00502973  
**Reviewer’s country:** China  
**Science editor:** Li-Jun Cui  
**Date sent for review:** 2018-02-13  
**Date reviewed:** 2018-02-26  
**Review time:** 13 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

**COMMENTS TO AUTHORS**

In this manuscript, the authors briefly reviewed the current status of HCC treatment by small molecular targeted medication and mAb therapy and proposed a potential roadmap of HCC treatment. This is relevant to the scope of the Journal and interesting. Some concerns existed and need to be addressed. 1. The English can be refined. 2. In the Neoantigen section, the author stated “it produces neoantigen signature that contains four amino acid strings of peptides.” Please provide the sequence of this four amino acid string. 3. In the Nivolumab section, what is HBC? 4. In the section of “Potential first line systemic treatment options in HCC”, “In the randomized phase III (REFLECT) study of lenvatinib vs sorafenib in first line treatment of unresectable HCC in 954 patients (1:1) with Child Pugh Class A.” is an incomplete sentence.